Financial Performance - The group's revenue decreased by 0.8% from RMB 997.8 million in the year ended December 31, 2021, to RMB 990.0 million in the year ended December 31, 2022[2]. - The group's profit before tax increased by 13.5% from RMB 210.6 million in the year ended December 31, 2021, to RMB 239.1 million in the year ended December 31, 2022, with a profit margin of 24.2%[2]. - The group's net profit rose by 16.2% from RMB 157.6 million in the year ended December 31, 2021, to RMB 183.2 million in the year ended December 31, 2022, with a net profit margin of 18.5%[2]. - The adjusted net profit under non-IFRS increased by 0.2% from RMB 185.9 million in the year ended December 31, 2021, to RMB 186.2 million in the year ended December 31, 2022, with an adjusted net profit margin of 18.8%[2]. - Basic earnings per share increased by 3.8% from RMB 0.26 in the year ended December 31, 2021, to RMB 0.27 in the year ended December 31, 2022[2]. Revenue Breakdown - Revenue from consumer ophthalmic services reached RMB 542.9 million, accounting for 54.8% of total revenue in 2022, up from 51.8% in 2021[11]. - Revenue from basic ophthalmic services was RMB 447.2 million, representing 45.2% of total revenue, down from 48.1% in the previous year[11]. - Revenue from consumer ophthalmic services increased by 5.0% from RMB 517.2 million to RMB 542.9 million, primarily due to an increase in patient volume during non-restricted periods of the COVID-19 pandemic[26]. - Revenue from basic ophthalmic services decreased by 6.8% from RMB 479.7 million to RMB 447.2 million, mainly due to pandemic prevention measures that limited patient access to treatments[27]. Operational Expansion - The number of ophthalmology hospitals operated by the group increased from 24 as of December 31, 2021, to 26 as of December 31, 2022[2]. - The group expanded its network by adding five new physical entities, including hospitals and optical centers, in 2022[6]. - The group completed the acquisition of four hospitals in Tangshan, enhancing its presence in the North China region and facilitating synergy with existing facilities[7]. - As of December 31, 2022, the group operated a network of 24 hospitals and 26 optical centers across five provinces and regions in China[8]. - The group plans to continue expanding its network, with hospitals expected to open in Zhangjiakou and other locations in 2023[22]. Customer Engagement and Services - Customer visits at optical centers decreased to 101,956 in 2022 from 119,040 in 2021[9]. - The average spending per outpatient visit decreased from RMB 647 in 2021 to RMB 626 in 2022[9]. - The average spending per inpatient visit decreased from RMB 7,415 in 2021 to RMB 7,244 in 2022[9]. - The average selling price at optical centers increased from RMB 692 in 2021 to RMB 746 in 2022[9]. Cost and Expenses - Selling and distribution expenses rose by 30.1% from RMB 47.1 million to RMB 61.3 million, attributed to increased marketing and advertising expenses in key regions[31]. - Administrative expenses decreased by 8.6% from RMB 177.3 million to RMB 162.0 million, mainly due to the absence of non-recurring listing expenses in the current year[32]. - The group's gross profit decreased by 3.1% from RMB 448.7 million to RMB 434.7 million, with the gross profit margin declining from 45.0% to 43.9%[29]. Employee and Workforce - As of December 31, 2022, the group has a total of 1,182 full-time medical professionals, including 242 doctors, 520 nurses, and 420 other professionals[17]. - The employee distribution includes 242 doctors (11.19%), 520 nurses (24.05%), and 420 other professionals (19.43%) as of December 31, 2022[70]. - The group has a total of 2,162 full-time employees as of December 31, 2022, with 1,182 being hospital professionals[69]. Financial Position and Assets - The group's cash and bank balances are essential for funding operations and expansion plans, including upgrading existing ophthalmology hospitals and constructing new ones[42]. - The net cash flow from operating activities for the year ended December 31, 2022, was RMB 273.4 million, while the net cash flow from investing activities was RMB (464.8) million[43]. - The company's total equity rose to RMB 2,298,473 thousand in 2022, up from RMB 2,128,406 thousand in 2021, indicating an increase of 8%[86]. - The company's inventory increased to RMB 52,415 thousand in 2022 from RMB 34,900 thousand in 2021, a growth of 50%[84]. Governance and Compliance - The company emphasizes the importance of corporate governance and compliance with international financial reporting standards[118]. - The audit committee consists of three independent non-executive directors, providing independent opinions on financial reporting and internal controls[63]. - The company established an Environmental, Social, and Governance (ESG) committee to enhance its governance standards and social recognition[76]. Future Outlook - The company anticipates that the negative impact of COVID-19 on its business will begin to diminish in the first quarter of 2023 as control measures are lifted[19]. - The company is focused on expanding its market presence and enhancing its product offerings in the ophthalmology sector[116]. - The company is actively pursuing new strategies for growth, including potential mergers and acquisitions in the healthcare industry[117].
朝聚眼科(02219) - 2022 - 年度业绩